ACT Brief: AI-Enabled End-to-End Trials, New Phase III Data in HIV, and a First-Line Shift in HER2-Positive Breast Cancer

In today’s ACT Brief, we close out our McKinsey interview series with a look at how AI could transform clinical trials end to end, review new Phase III data supporting Gilead’s investigational HIV regimen, and examine an FDA approval that reshapes first-line treatment for HER2-positive metastatic breast cancer.